OmniAb (NASDAQ:OABI) Issues Quarterly Earnings Results

OmniAb (NASDAQ:OABI) announced its quarterly earnings results on Friday. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.01, FiscalAI reports. The company had revenue of $3.99 million during the quarter, compared to analyst estimates of $3.49 million. OmniAb had a negative return on equity of 16.59% and a negative net margin of 115.12%.

Here are the key takeaways from OmniAb’s conference call:

• 2026 guidance was raised: OmniAb increased revenue guidance to $35 million–$39 million, reduced operating-expense guidance to $83 million–$87 million, and expects year-end cash of $53 million–$57 million, implying roughly break-even net cash flow for the year.
• The company signed a new Eli Lilly ion-channel license that includes an upfront payment, up to $370 million in potential milestones, and tiered royalties; related service revenue is expected to begin in the fourth quarter.
• Partner momentum continued, with 111 active partners and 433 active programs at quarter-end. OmniAb also reported 34 active clinical programs or approved products, more than $3 billion in contracted potential milestones, and the recent Chinese approval of batoclimab.
• xPloration gained commercial traction with another instrument placement at a major pharmaceutical company. Management expects xPloration revenue of $2 million–$3 million in 2026, followed by a doubling in 2027 and again in 2028 as consumables, software, and service revenue build.
• Third-quarter revenue rose to $4.0 million from $2.2 million, while net loss narrowed modestly to $15.7 million, or $0.12 per share. Management expects milestones to remain the largest revenue contributor over the next several years, with royalties potentially becoming a larger growth driver as assets such as IMVT-1402 advance.

OmniAb Price Performance

NASDAQ OABI traded down $0.12 on Friday, reaching $5.11. The company had a trading volume of 2,113,864 shares, compared to its average volume of 1,360,653. OmniAb has a 1 year low of $1.30 and a 1 year high of $5.43. The firm has a 50-day moving average of $4.65 and a 200-day moving average of $2.71. The firm has a market capitalization of $739.84 million, a PE ratio of -14.19 and a beta of 0.60.

Wall Street Analyst Weigh In

OABI has been the topic of several research reports. Weiss Ratings upgraded shares of OmniAb from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. Leerink Partners boosted their price objective on shares of OmniAb from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of OmniAb in a research report on Monday, August 17th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $11.50.

OmniAb Company Profile

OmniAb, Inc is a biotechnology company that develops and licenses antibody discovery technologies for use in drug research and development. Its platform is designed to help biopharmaceutical companies generate fully human and species-diverse antibodies that can be evaluated as potential treatments for a range of diseases.

The company’s technology portfolio includes genetically engineered animal platforms, such as OmniRat, OmniMouse and OmniChicken, which are used to produce antibody candidates against challenging biological targets.